FY2024 Earnings Estimate for TVTX Issued By Leerink Partnrs

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Leerink Partnrs boosted their FY2024 earnings estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($3.99) for the year, up from their previous forecast of ($4.03). The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share. Leerink Partnrs also issued estimates for Travere Therapeutics’ Q4 2024 earnings at ($0.62) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at $0.32 EPS and FY2025 earnings at ($1.01) EPS.

TVTX has been the subject of a number of other reports. Scotiabank increased their price target on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Barclays raised their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Piper Sandler increased their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Guggenheim upped their target price on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Stock Performance

TVTX stock opened at $19.46 on Wednesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $20.33. The business has a 50 day simple moving average of $18.23 and a two-hundred day simple moving average of $14.75. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.28 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.01. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. Travere Therapeutics’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.17) EPS.

Insider Transactions at Travere Therapeutics

In related news, insider Jula Inrig sold 2,066 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the transaction, the insider now directly owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This represents a 3.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This represents a 21.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,596 shares of company stock worth $527,262. Insiders own 4.06% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Aigen Investment Management LP acquired a new position in Travere Therapeutics in the third quarter valued at approximately $170,000. Oppenheimer & Co. Inc. acquired a new position in shares of Travere Therapeutics in the 3rd quarter valued at $673,000. Millennium Management LLC boosted its holdings in Travere Therapeutics by 33.9% during the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after buying an additional 747,406 shares in the last quarter. FMR LLC boosted its holdings in Travere Therapeutics by 27.5% during the third quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after buying an additional 31,772 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Travere Therapeutics by 30.2% during the third quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after buying an additional 167,100 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.